Anzeige
Mehr »
Montag, 18.05.2026 - Börsentäglich über 12.000 News
China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
336 Leser
Artikel bewerten:
(1)

Indegene Inc: Industry commercialization expert, Nancy Phelan joins Indegene as SVP leading its global omnichannel commercialization business

PRINCETON, N.J. and BANGALORE, India, May 12, 2022 (GLOBE NEWSWIRE) -- Indegene, a technology-led healthcare solutions provider today announced the appointment of industry commercialization expert, Nancy Phelan, as SVP for its global digital-first omnichannel commercialization business, based in the US.

Nancy is a recognized life sciences thought leader, digital pioneer and change agent with 25+ years of experience in commercial strategy and operations. Prior to Indegene, she co-led the Transformation Management Office at Novartis as its Vice President, Business Transformation and previously was VP, Head, Neuroscience Franchise Patient and Specialty Services. A passionate patient and customer champion, Nancy previously was CEO, Adhera Therapeutics and in the past, has held diverse, senior leadership positions in customer and market engagement, communications and marketing at Pfizer, Wyeth, Bristol-Myers Squibb and Schering-Plough. She also brings significant advisor and board experience from a diverse set of public and private companies and organizations including, FemmePharma Consumer Healthcare, Eved, HATCH@Takeda and the Pharma Digital Health Roundtable.

At Indegene, Nancy will lead the omnichannel commercialization business organization that partners with leading biopharma, emerging biotech and medical technology organizations as they rethink their Go-To-Market (GTM) models for Healthcare Professionals (HCPs) and Patients. Through a digital-first omnichannel engagement model, Indegene helps life sciences organizations optimize their field force deployments and augment stakeholder engagement.

FY22_0250_Social-Media-Post_NancyPhelan_1200x627px_v3

Healthcare Professionals (HCPs) are increasingly digital-savvy, and Indegene's omnichannel commercialization business employs an innovative, virtual Digital Rep Equivalence (DRE) model to deliver impact equivalent to that of field sales reps, while enhancing customer experience. It leverages advanced analytics and proprietary IP to craft a data-driven brand, content and campaign strategy which offers the life sciences industry effective, efficient and differentiated ways to engage customers.

Announcing Nancy's appointment, Gaurav Kapoor, Cofounder and EVP, Indegene said, "Life sciences organizations are exploring newer ways of going to market and elevating their customer experience. Nancy's experience leading large-scale business transformation will be especially important to translate their bold visions into reality. She has been an early adopter of technology with many branded and unbranded digital campaigns to her credit, and brings a first-hand knowledge of driving commercial model innovation at Pfizer and Bristol-Myers Squibb. We are thrilled to have Nancy on-board to enable our clients' new go-to-market models and drive business impact."

Nancy Phelan, SVP, Indegene's omnichannel commercialization business added, "I am very excited to join Indegene at a time when life sciences organizations are innovating at the commercial end of their value chain, just like they do at the R&D end. I am impressed with the Indegene team's application of advanced analytics to understand HCPs' digital affinity, develop and deploy omnichannel engagement plans, and optimize them continuously to maximize the benefits from digital, virtual sales and field rep channels and to further build and grow Indegene's patient offerings. I am excited to leverage this differentiated technology and the team's medical expertise to create win-win propositions for our clients and for Indegene."

About Indegene
Indegene is a technology-led healthcare solutions provider. It combines deep industry expertise with fit-for-purpose technology in an agile and scalable operating model. Many of the leading, global healthcare organizations rely on Indegene to deliver effective and efficient clinical, medical and commercial outcomes every day. From strategy to execution, Indegene enables healthcare organizations be future ready. To learn more about how Indegene delivers on its purpose, please visit www.indegene.com

For media enquiries, please contact
Ruchi Wadhwa
ruchi.wadhwa@indegene.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/57b2d408-ecb7-4a6d-8daf-f831396edc91


© 2022 GlobeNewswire (Europe)
Vergessen Sie Gold, Silber und Öl: Nächste Megarallye startet!
Die Märkte feiern neue Rekorde – doch im Hintergrund braut sich eine Entwicklung zusammen, die alles verändern könnte. Die anhaltende Sperrung der Straße von Hormus sorgt laut IEA für eine der größten Energiekrisen aller Zeiten. Gleichzeitig schießen die Preise für Düngemittel und Agrarrohstoffe bereits nach oben.

Damit droht ein perfekter Sturm: steigende Energiepreise, explodierende Produktionskosten und ein möglicher Super-El-Nino, der weltweit Ernten gefährdet. Erste Auswirkungen sind längst sichtbar – Weizen, Soja und Kakao verteuern sich deutlich, während Lebensmittelpreise vor dem nächsten Sprung stehen könnten.

Für Anleger bedeutet das nicht nur Risiken, sondern enorme Chancen. Denn während klassische Märkte unter Druck geraten könnten, entsteht auf den Feldern und Plantagen der nächste große Rohstoffzyklus. Wer sich jetzt richtig positioniert, kann von einer Entwicklung profitieren, die weit über Öl und Metalle hinausgeht.

In unserem aktuellen Spezialreport stellen wir drei Aktien vor, die besonders aussichtsreich sind, um von diesem Trend zu profitieren – solide positioniert, strategisch relevant und mit erheblichem Aufwärtspotenzial.



Jetzt den kostenlosen Report sichern – bevor der Agrar-Boom voll durchschlägt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.